Safety and efficacy of tazarotene foam for the treatment of acne vulgaris
Erica L Epstein, Linda Stein Gold
Henry Ford Hospital, Detroit, MI, USA
Background: Tazarotene foam is the first topical retinoid foam approved for the treatment of acne vulgaris.
Objective: To review the safety and efficacy studies of tazarotene foam in the treatment of moderate to severe acne.
Methods: Five Phase I safety studies in normal controls are reviewed and two Phase III safety and efficacy studies in patients with moderate to severe acne are reviewed.
Conclusion: Tazarotene foam, 0.1% was effective in the treatment of moderate to severe acne vulgaris with an acceptable tolerability profile. This treatment provides a cosmetically favorable alternative for topical retinoid therapy.
Keywords: tazarotene, acne, foam, topical retinoid
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]